Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

van Meerbeeck, 2005, J Clin Oncol, 23, 6881, 10.1200/JCO.20005.14.589

Karrison, 2007, Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM), J Clin Oncol, 25

Ohta, 1999, VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumors, Br J Cancer, 81, 54, 10.1038/sj.bjc.6690650

Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059

Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9

Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145

Dubey, 2010, A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307, J Thoracic Oncol, 5, 1655, 10.1097/JTO.0b013e3181ec18db

Nowak, 2010, Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM), J Clin Oncol, 28

Garland, 2007, Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study, J Clin Oncol, 25, 2406, 10.1200/JCO.2006.09.7634

Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887

Tsao, 2011, A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria, J Thor Oncol, 6, 598, 10.1097/JTO.0b013e318208c83d

Wheatley-Price, 2010, Soluble mesothelin-related peptide and osteopontin as markers of response in malignant pleural mesothelioma, J Clin Oncol, 28, 3316, 10.1200/JCO.2009.26.9944

Francis, 2007, Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans, J Nuclear Med, 48, 1449, 10.2967/jnumed.107.042333